A comparative analysis of genetic and epigenetic events of breast and ovarian cancer related to tumorigenesis

International Journal of Molecular Sciences

Volumn 17, Issue 5, 2016, Pages

  Longacre, McKenna ^a   Snyder, Nicole A ^b   Housman, Genevieve ^c   Leary, Meghan ^d   Lapinska, Karolina ^d   Heerboth, Sarah ^e   Willbanks, Amber ^d   Sarkar, Sibaji ^d  

^a HARVARD MEDICAL SCHOOL   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c ARIZONA STATE UNIVERSITY   (United States)

^d BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Breast cancer; Epigenetics; Ovarian cancer

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; CARBOPLATIN; CISPLATIN; DNA METHYLTRANSFERASE 1; HEPATOCYTE NUCLEAR FACTOR 3ALPHA; METHOTREXATE; MICRORNA; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; STROMAL CELL DERIVED FACTOR 1; TAMOXIFEN; TRANSCRIPTION FACTOR EZH2; TRASTUZUMAB; VINCRISTINE; HISTONE;

BREAST CANCER; CANCER GROWTH; CARCINOGENESIS; CELL CYCLE REGULATION; COMPARATIVE STUDY; DNA DAMAGE; EPIGENETICS; GENE MUTATION; GENE OVEREXPRESSION; GENETICS; HISTONE METHYLATION; HUMAN; OVARY CANCER; REVIEW; BREAST NEOPLASMS; DRUG RESISTANCE; FEMALE; GENE EXPRESSION REGULATION; GENETIC EPIGENESIS; GENETIC VARIATION; OVARIAN NEOPLASMS; TUMOR MICROENVIRONMENT;

BREAST NEOPLASMS; DRUG RESISTANCE, NEOPLASM; EPIGENESIS, GENETIC; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC VARIATION; HISTONES; HUMANS; OVARIAN NEOPLASMS; TUMOR MICROENVIRONMENT;

EID: 84969234290     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms17050759     Document Type: Review

References (101)

1. Langerød, A.; Zhao, H.; Borgan, Ø.; Nesland, J.M.; Bukholm, I.R.; Ikdahl, T.; Kåresen, R.; Børresen-Dale, A.-L.; Jeffrey, S.S. TP53 mutation status and gene expression profiles are powerful prognostic markers of breast cancer. Breast Cancer Res. 2007, 9. [CrossRef] [PubMed]
2. Stephens, P.J.; Tarpey, P.S.; Davies, H.; Van Loo, P.; Greenman, C.; Wedge, D.C.; Nik-Zainal, S.; Martin, S.; Varela, I.; Bignell, G.R.; et al. The landscape of cancer genes and mutational processes in breast cancer. Nature 2012, 486, 400-404. [CrossRef] [PubMed]
3. Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature 2012, 490, 61-70.
4. Burgess, M.; Puhalla, S. BRCA 1/2-Mutation related and sporadic breast and ovarian cancers: More alike than different. Front. Oncol. 2014, 4. [CrossRef] [PubMed]
5. Cancer Genome Atlas Network. Integrated genomic analyses of ovarian carcinoma. Nature 2011, 474, 609-615.
6. Sadeqzadeh, E.; de Bock, D.E.; Thorne, R.F. Sleeping giants: Emerging roles for cadherins in health and disease. Med. Res. Rev. 2014, 34, 190-221. [CrossRef] [PubMed]
7. Oeschger, F.M.; Wang, W.; Lee, S.; Garcia-Moreno, F.; Goffinet, A.M.; Arbones, M.I.; Rakic, S.; Molnar, Z. Gene expression analysis of the embryonic subplate. Cereb. Cortex 2012, 6, 1343-1359. [CrossRef] [PubMed]
8. Ekumi, K.M.; Paculova, H.; Lenasi, T.; Popichalova, V.; Bosken, C.A.; Rybarikova, J.; Bryja, V.; Geyer, M.; Blazek, D.; Barboric, M. Ovarian carcinoma CKD12 mutations misregulate expression of DNA repair genes via Cdk12/CycK complex. Nucleic Acids Res. 2015, 5, 2575-2589. [CrossRef] [PubMed]
9. Koff, A.; Giordano, A.; Desai, D.; Yamashita, K.; Harper, J.W.; Elledge, S.; Nishimoto, T.; Morgan, D.O.; Franza, B.R.; Roberts, J.M. Formation and activation of a cyclin E-cdk2 complex during the G1 phase of the human cell cycle. Science 1992, 257, 1689-1694. [CrossRef] [PubMed]
10. Glass, C.; Wilson, M.; Gonzalez, R.; Zhang, Y.; Perkins, A.S. The role of EVI1 in myeloid malignancies. Blood Cells Mol. Dis. 2014, 53, 67-76. [CrossRef] [PubMed]
11. Gong, F.; Chiu, L.-Y.; Cox, B.; Aymard, F.; Clouaire, T.; Leung, J.W.; Cammarata, M.; Perez, M.; Agarwal, P.; Brodbelt, J.S.; et al. Screen identifies bromodomain protein ZMYND8 in chromatin recognition of transcription-associated DNA damage that promotes homologous recombination. Genes Dev. 2015, 29, 197-211. [CrossRef] [PubMed]
12. Ling, F.; Kang, B.; Sun, X. Id proteins: Small molecules, mighty regulators. Curr. Top. Dev. Biol. 2014, 110, 189-216. [PubMed]
13. Mittag, J.; Winterhager, E.; Bauer, K.; Grummer, R. Congenital hypothyroid femail pax8-deficient mice are infertile despite thyroid hormone replacement therapy. Endocrinology 2007, 148, 719-725. [CrossRef] [PubMed]
14. Dydensborg, A.B.; Rose, A.A.N.;Wilson, B.J.; Grote, D.; Paquet, M.; Giguère, V.; Siegel, P.M.; Bouchard, M. GATA3 inhibits breast cancer growth and pulmonary breast cancer metastasis. Oncogene 2009, 28, 2634-2642. [CrossRef] [PubMed]
15. Ford, D.J.; Dingwall, A.K. The cancer COMPASS: Navigating the functions of MLL complexes in cancer. Cancer Genet. 2015, 208, 178-191. [CrossRef] [PubMed]
16. Rowley, M.; Grothey, E.; Couch, F.J. The role of Tbx2 and Tbx3 in mammary development and tumorigenesis. J. Mammary Gland Biol. Neoplasia 2004, 2, 109-118. [CrossRef] [PubMed]
17. Melko, M.; Nguyen, L.S.; Shaw, M.; Jolly, L.; Bardoni, B.; Gecz, J. Loss of FMR2 further emphasizes the link between deregulation of immediate early response genes FOS and JUN and intellectual disability. Hum. Mol. Genet. 2013, 22, 2984-2991. [CrossRef] [PubMed]
18. Prat, J. New insights into ovarian cancer pathology. Ann. Oncol. 2012, 23, x111-x117. [CrossRef] [PubMed]
19. Wang, Y.; Helland, A.; Holm, R.; Skomedal, H.; Abeler, V.M.; Danielsen, H.E.; Tropé, C.G.; Børresen-Dale, A.-L.; Kristensen, G.B. TP53 mutations in early-stage ovarian carcinoma, relation to long-term survival. Br. J. Cancer 2004, 90, 678-685. [CrossRef] [PubMed]
20. Olivier, M.; Hollstein, M.; Hainaut, P. TP53 mutations in human cancers: Origins, consequences, and clinical use. Cold Spring Harb. Perspect. Biol. 2010, 2, a001008. [CrossRef] [PubMeds]
21. Wang, Y.; Kringen, P.; Kristensen, G.B.; Holm, R.; Baekelandt, M.M.O.; Olivier, M.; Skomedal, H.; Hainaut, P.; Tropé, C.G.; Abeler, V.M.; et al. Effect of the codon 72 polymorphism (c.215G>C, p.Arg72Pro) in combination with somatic sequence variants in the TP53 gene on survival in patients with advanced ovarian carcinoma. Hum. Mutat. 2004, 24, 21-34. [CrossRef] [PubMed]
22. Vogelstein, B.; Lane, D.; Levine, A.J. Surfing the p53 network. Nature 2000, 408, 307-310. [CrossRef] [PubMed]
23. Finch, A.; Beiner, M.; Lubinski, J.; Lynch, H.T.; Moller, P.; Rosen, B.; Murphy, J.; Ghadirian, P.; Friedman, E.; Foulkes, W.D.; et al. Hereditary Ovarian Cancer Clinical Study Group. Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 mutation. JAMA 2006, 296, 185-192. [CrossRef] [PubMed]
24. Ferrone, C.R.; Levine, D.A.; Tang, L.H.; Allen, P.J.; Jarnagin, W.; Brennan, M.F.; Offit, K.; Robson, M.E. BRCA germline mutations in Jewish patients with pancreatic adenocarcinoma. J. Clin. Oncol. 2009, 27, 433-438. [CrossRef] [PubMed]
25. Howlett, N.G.; Taniguchi, T.; Olson, S.; Cox, B.;Waisfisz, Q.; De Die-Smulders, C.; Persky, N.; Grompe, M.; Joenje, H.; Pals, G.; et al. Biallelic inactivation of BRCA2 in Fanconi anemia. Science 2002, 297, 606-609. [CrossRef] [PubMed]
26. Sawyer, S.L.; Tian, L.; Kähkönen, M.; Schwartzentruber, J.; Kircher, M.; University of Washington Centre for Mendelian Genomics; FORGE Canada Consortium; Majewski, J.; Dyment, D.A.; Innes, A.M.; et al. Biallelic mutations in BRCA1 cause a new Fanconi anemia subtype. Cancer Discov. 2015, 5, 135-142. [CrossRef] [PubMed]
27. Severson, T.M.; Peeters, J.; Majewski, I.; Michaut, M.; Bosma, A.; Schouten, P.C.; Chin, S.F.; Pereira, B.; Goldgraben, M.A.; Bismeijer, T.; et al. BRCA1-line signature in triple negative breast cancer: Molecular and clinical characterization reveals subgroups with therapeutic potential. Mol. Oncol. 2015, 9, 1529-1538. [CrossRef] [PubMed]
28. Lips, E.H.; Laddach, N.; Savola, S.P.; Vollebergh, M.A.; Oonk, A.M.; Imholz, A.L.; Wessels, L.F.; Wesseling, J.; Nederlof, P.M.; Rodenhuis, S. Quantitative copy number analysis by Multiplex Ligation-dependent Probe Amplification (MLPA) of BRCA1-associated breast cancer regions identifies BRCAness. Breast Cancer Res. 2011, 13, R107. [CrossRef] [PubMed]
29. Calin, G.A.; Sevignani, C.; Dumitru, C.D.; Hyslop, T.; Noch, E.; Yendamuri, S.; Shimizu, M.; Rattan, S.; Bullrich, F.; Negrini, M.; et al. Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc. Natl. Acad. Sci. USA 2004, 101, 2999-3004. [CrossRef] [PubMed]
30. Nagaraja, A.K.; Creighton, C.J.; Yu, Z.; Zhu, H.; Gunaratne, P.H.; Reid, J.G.; Olokpa, E.; Itamochi, H.; Ueno, N.T.; Hawkins, S.M.; et al. A link between mir-100 and FRAP1/mTOR in clear cell ovarian cancer. Mol. Endocrinol. 2010, 24, 447-463. [CrossRef] [PubMed]
31. Iorio, M.V.; Ferracin, M.; Liu, C.-G.; Veronese, A.; Spizzo, R.; Sabbioni, S.; Magri, E.; Pedriali, M.; Fabbri, M.; Campiglio, M.; et al. MicroRNA gene expression deregulation in human breast cancer. Cancer Res. 2005, 65, 7065-7070. [CrossRef] [PubMed]
32. Derfoul, A.; Juan, A.H.; Difilippantonio, M.J.; Palanisamy, N.; Ried, T.; Sartorelli, V. Decreased microRNA-214 levels in breast cancer cells coincides with increased cell proliferation, invasion and accumulation of the Polycomb Ezh2 methyltransferase. Carcinogenesis 2011, 32, 1607-1614. [CrossRef] [PubMed]
33. O’Day, E.; Lal, A. MicroRNAs and their target gene networks in breast cancer. Breast Cancer Res. 2010, 12, 201. [CrossRef] [PubMed]
34. Song, S.J.; Poliseno, L.; Song, M.S.; Ala, U.; Webster, K.; Ng, C.; Beringer, G.; Brikbak, N.J.; Yuan, X.; Cantley, L.C.; et al. microRNA-antagonism regulates breast cancer stemness and metastasis via TET family dependent chromatin remodeling. Cell 2013, 154, 311-324. [CrossRef] [PubMed]
35. Song, S.J.; Ito, K.; Ala, U.; Kats, L.; Webster, K.; Sun, S.M.; Jongen-Lavrencic, M.; Manova-Todorova, K.; Teruya-Feldstein, J.; Avigan, D.E.; et al. The oncogenic microRNA miR-22 targets the TET2 tumor suppressor to promote hematopoietic stem cell self-renewal and transformation. Cell Stem Cell 2013, 13, 87-101. [CrossRef] [PubMed]
36. Yu, F.; Jiao, Y.; Zhu, Y.;Wang, Y.; Zhu, J.; Cui, X.; Liu, Y.; He, Y.; Park, E.-Y.; Zhang, H.; et al. MicroRNA 34c gene down-regulation via DNA methylation promotes self-renewal and epithelial-mesenchymal transition in breast tumor-initiating cells. J. Biol. Chem. 2012, 287, 465-473. [CrossRef] [PubMed]
37. Yang, H.; Kong, W.; He, L.; Zhao, J.-J.; O’Donnell, J.D.; Wang, J.; Wenham, R.M.; Coppola, D.; Kruk, P.A.; Nicosia, S.V.; et al. MicroRNA expression profiling in human ovarian cancer: MiR-214 induces cell survival and cisplatin resistance by targeting PTEN. Cancer Res. 2008, 68, 425-433. [CrossRef] [PubMed]
38. Park, S.-M.; Gaur, A.B.; Lengyel, E.; Peter, M.E. The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2. Genes Dev. 2008, 22, 894-907. [CrossRef] [PubMed]
39. Giannakakis, A.; Sandaltzopoulos, R.; Greshock, J.; Liang, S.; Huang, J.; Hasegawa, K.; Li, C.; O’Brien-Jenkins, A.; Katsaros, D.; Weber, B.L.; et al. miR-210 links hypoxia with cell cycle regulation and is deleted in human epithelial ovarian cancer. Cancer Biol. Ther. 2008, 7, 255-264. [CrossRef] [PubMed]
40. Laios, A.; O’Toole, S.; Flavin, R.; Martin, C.; Kelly, L.; Ring, M.; Finn, S.P.; Barrett, C.; Loda, M.; Gleeson, N.; et al. Potential role of miR-9 and miR-223 in recurrent ovarian cancer. Mol. Cancer 2008, 7, 35. [CrossRef] [PubMed]
41. Adams, B.D.; Furneaux, H.; White, B.A. The micro-ribonucleic acid (miRNA) miR-206 targets the human estrogen receptor-alpha (ERalpha) and represses ERalpha messenger RNA and protein expression in breast cancer cell lines. Mol. Endocrinol. 2007, 21, 1132-1147. [CrossRef] [PubMed]
42. Qin, C.; Huang, R.;Wang, Z. Potential role of miR-100 in cancer diagnosis, prognosis, and therapy. Tumor Biol. 2015, 36, 1403-1409. [CrossRef] [PubMed]
43. Zhao, H.;Wei,W.; Sun, Y.; Gao, J.;Wang, Q.; Zheng, J. MicroRNA-9 promotes tumorigenesis and mediates sensitivity to cisplatin in primary epithelial ovarian cancer. Tumor Biol. 2015, 36, 6867-6873. [CrossRef] [PubMed]
44. Guan, X.; Gao, Y.; Zhou, J.; Wang, J.; Zheng, F.; Guo, F.; Chang, A.; Li, X.; Wang, B. miR-233 regulates adipogenic and osteogenic differentiation of mesenchymal stem cells through a C/EBPs/miR-233/FGFR2 regualtory feedback loop. Stem Cells 2015, 33, 1589-1600. [CrossRef] [PubMed]
45. Zuberi, M.; Mir, R.; Das, J.; Ahmad, I.; Javid, J.; Yadav, P.; Masroor, M.; Ahmad, S.; Ray, P.C.; Saxena, A. Expression of serum miR-200a, miR-200b, and miR-200c as candidate biomarkers in epithelial ovarian cancer and their associationwith clinicopathological features. Clin. Transl. Oncol. 2015, 17, 779-787. [CrossRef] [PubMed]
46. Shimono, Y.; Mukohyama, J.; Nakamura, S.; Minami, H. MicroRNA regulation of human breast cancer stem cells. J. Clin. Med. 2016, 5, 2. [CrossRef] [PubMed]
47. Zhao, G.; Guo, Y.; Chen, Z.; Wang, Y.; Yang, C.; Dudas, A.; Du, Z.; Liu, W.; Zou, Y.; Szabo, E.; et al. miR-203 functions as a tumor suppressor by inhibiting epithelial to mesenchymal transition in ovarian cancer. J. Cancer Sci. Ther. 2015, 7, 34-43. [PubMed]
48. Zhang, S.; Lu, Z.; Unruh, A.K.; Ivan, C.; Baggerly, K.A.; Calin, G.A.; Li, Z.; Bast, R.C.; Le, X. Clinically relevant microRNAs in ovarian cancer. Mol. Cancer Res. 2015, 13, 393-401. [CrossRef] [PubMed]
49. Dahl, K.D.C.; Dahl, R.; Kruichak, J.N.; Hudson, L.G. The epidermal growth factor receptor responsive miR-125a represses mesenchymal morphology in ovarian cancer cells. Neoplasia 2009, 11, 1208-1215. [CrossRef]
50. Byler, S.; Sarkar, S. Do epigenetic drug treatments hold the key to killing cancer progenitor cells? Epigenomics 2014, 6, 161-165. [CrossRef] [PubMed]
51. Elsheikh, S.E.; Green, A.R.; Rakha, E.A.; Powe, D.G.; Ahmed, R.A.; Collins, H.M.; Soria, D.; Garibaldi, J.M.; Paish, C.E.; Ammar, A.A.; et al. Global histone modifications in breast cancer correlate with tumor phenotypes, prognostic factors, and patient outcome. Cancer Res. 2009, 69, 3802-3809. [CrossRef] [PubMed]
52. Liu, L.; Kimball, S.; Liu, H.; Holowatyj, A.; Yang, Z.Q. Genetic alterations of histone lysine methyltransferases and their significance in breast cancer. Oncotarget 2014, 6, 2466-2482. [CrossRef] [PubMed]
53. Zhao, Q.Y.; Lei, P.J.; Zhang, X.; Zheng, J.Y.; Wang, H.Y.; Zhao, J.; Li, Y.M.; Ye, M.; Li, L.; Wei, G.; et al. Global histone modification profiling reveals the epigenomic dynamics during malignant transformation in a four-stage breast cancer model. Clin. Epigenet. 2016, 8, 34. [CrossRef] [PubMed]
54. Marsh, D.J.; Shah, J.S.; Cole, A.J. Histones and Their Modifications in Ovarian Cancer-Drivers of Disease and Therapeutic Targets. Front. Oncol. 2014, 4, 144. [PubMed]
55. Rhie, S.K.; Hazelett, D.J.; Coetzee, S.G.; Yan, C.; Noushmehr, H.; Coetzee, G.A. Nucleosome positioning and histone modifications define relationships between regulatory elements and nearby gene expression in breast epithelial cells. BMC Genom. 2014, 15, 331. [CrossRef] [PubMed]
56. Chase, A.; Cross, N.C.P. Aberrations of EZH2 in cancer. Clin. Cancer Res. 2011, 17, 2613-2618. [CrossRef] [PubMed]
57. Kron, K.J.; Bailey, S.D.; Lupien, M. Enhancer altertions in cancer: A source for a cell identity crisis. Genome Med. 2014, 9, 77. [CrossRef] [PubMed]
58. Niederriter, A.R.; Varshney, A.; Parker, S.C.; Martin, D.M. Super enhancers in cancers, complex diseases, and developmental disorders. Genes (Basel) 2015, 4, 1183-1200. [CrossRef] [PubMed]
59. Dowen, J.M.; Fan, Z.P.; Hnisz, D.; Ren, G.; Abraham, B.J.; Zhang, L.N.; Weintraub, A.S.; Schuijers, J.; Lee, J.I.; Zhao, K.; et al. Control of cell identity genes occurs in insulated neighborhoods in mammalian chromosomes. Cell 2014, 159, 374-387. [CrossRef] [PubMed]
60. Wang, H.; Maurano, M.T.; Qu, H.; Varley, K.E.; Gertz, J.; Pauli, F.; Lee, K.; Canfield, T.; Weaver, M.; Sandstrom, R.; et al. Widespread plasticity in CTCF occupancy linked to DNA methylation. Genome Res. 2012, 22, 1680-1688. [CrossRef] [PubMed]
61. Sarkar, S.; Goldgar, S.; Byler, S.; Rosenthal, S.; Heerboth, S. Demethylation and re-expression of epigenetically silenced tumor suppressor genes: Sensitization of cancer cells by combination therapy. Epigenomics 2013, 5, 87-94. [CrossRef] [PubMed]
62. Sarkar, S.; Horn, G.; Moulton, K.; Oza, A.; Byler, S.; Kokolus, S.; Longacre, M. Cancer development, progression, and therapy: An epigenetic overview. Int. J. Mol. Sci. 2013, 14, 21087-21113. [CrossRef] [PubMed]
63. Koukoura, O.; Spandidos, D.A.; Daponte, A.; Sifakis, S. DNA methylation profiles in ovarian cancer: Implication in diagnosis and therapy (Review). Mol. Med. Rep. 2014, 10, 3-9. [CrossRef] [PubMed]
64. Lavaud, P.; Andre, F. Strategies to overcome trastuzumab resistance in HER2-overexpressing breast cancers: Focus on new data from clinical trials. BMC Med. 2014, 12, 132. [CrossRef] [PubMed]
65. Feng, Q.; Deftereos, G. DNA hypermethylation, Her-2/neu overexpression and p53 mutations in ovarian carcinoma. Gynecol. Oncol. 2008, 111, 320-329. [CrossRef] [PubMed]
66. Fiegl, H.; Millinger, S.; Goebel, G.; Müller-Holzner, E.; Marth, C.; Laird, P.W.;Widschwendter, M. Breast cancer DNA methylation profiles in cancer cells and tumor stroma: Association with HER-2/neu status in primary breast cancer. Cancer Res. 2006, 66, 29-33. [CrossRef] [PubMed]
67. Lindqvist, B.M.; Wingren, S.; Motlagh, P.B.; Nilsson, T.K. Whole genome DNA methylation signature of HER2-positive breast cancer. Epigenetics 2014, 9, 1149-1162. [CrossRef] [PubMed]
68. Rodenhiser, D.I.; Andrews, J.; Kennette, W.; Sadikovic, B.; Mendlowitz, A.; Tuck, A.B.; Chambers, A.F. Epigenetic mapping and functional analysis in a breast cancer metastasis model using whole-genome promoter tiling microarrays. Breast Cancer Res. 2008, 10. [CrossRef] [PubMed]
69. Graff, J.R.; Herman, J.G.; Lapidus, R.G.; Chopra, H.; Xu, R.; Jarrard, D.F.; Isaacs, W.B.; Pitha, P.M.; Davidson, N.E.; Baylin, S.B. E-cadherin expression is silenced by DNA hypermethylation in human breast and prostate carcinomas. Cancer Res. 1995, 55, 5195-5199. [PubMed]
70. Do, S.-I.; Ko, E.; Kang, S.Y.; Lee, J.E.; Nam, S.J.; Cho, E.Y.; Kim, D.-H. Aberrant DNA methylation of integrin κ4 in human breast cancer. Tumour Biol. 2014, 35, 7079-7084. [CrossRef] [PubMed]
71. Lal, S.; Kersch, C.; Beeson, K.A.;Wu, Y.J.; Muldoon, L.L.; Neuwelt, E.A. Interactions between κv-integrin and HER2 and their role in the invasive phenotype of breast cancer cells in vitro and in rat brain. PLoS ONE 2015, 10, e0131842. [CrossRef] [PubMed]
72. Sarkar, S.; Abujamra, A.L.; Loew, J.E.; Forman, L.W.; Perrine, S.P.; Faller, D.V. Histone deacetylase inhibitors reverse CpG methylation by regulating DNMT1 through ERK signaling. Anticancer Res. 2011, 31, 2723-2732. [PubMed]
73. Zuo, T.; Liu, T.-M.; Lan, X.;Weng, Y.-I.; Shen, R.; Gu, F.; Huang, Y.-W.; Liyanarachchi, S.; Deatherage, D.E.; Hsu, P.-Y.; et al. Epigenetic silencing mediated through activated PI3K/AKT signaling in breast cancer. Cancer Res. 2011, 71, 1752-1762. [CrossRef] [PubMed]
74. Robertson, K.D.; Keyomarsi, K.; Gonzales, F.A.; Velicescu, M.; Jones, P.A. Differential mRNA expression of the human DNA methyltransferases (DNMTs) 1, 3a and 3b during the G(0)/G(1) to S phase transition in normal and tumor cells. Nucleic Acids Res. 2000, 28, 2108-2113. [CrossRef] [PubMed]
75. Samorodnitsky, E.; Ghosh, E.; Mazumder, S.; Sarkar, S. Methylation by DNMT1 is more Efficient in Chronic Lymphocytic Lymphoma Cells than in Normal Cells. J. Proteom. Bioinform. 2014, 1. [CrossRef]
76. Zhao, Z.; Li, S.; Song, E.; Liu, S. The roles of ncRNAs and histone-modifiers in regulating breast cancer stem cells. Protein Cell 2016, 7, 89-99. [CrossRef] [PubMed]
77. Yang, G.; Rosen, D.G.; Zhang, Z.; Bast, R.C.; Mills, G.B.; Colacino, J.A.; Mercado-Uribe, I.; Liu, J. The chemokine growth-regulated oncogene 1 (Gro-1) links RAS signaling to the senescence of stromal fibroblasts and ovarian tumorigenesis. Proc. Natl. Acad. Sci. USA 2006, 103, 16472-16477. [CrossRef] [PubMed]
78. Jiang, Y.; Gauthier, A.; Postma, M.J.; Ribassin-Majed, L.; Largeron, N.; Bresse, X. A critical review of cost-effectiveness analyses of vaccinating males against human papillomavirus. Hum. Vaccines Immunother. 2013, 9, 2285-2295. [CrossRef]
79. Matei, D.; Sill, M.W.; Lankes, H.A.; DeGeest, K.; Bristow, R.E.; Mutch, D.; Yamada, S.D.; Cohn, D.; Calvert, V.; Farley, J.; et al. Activity of sorafenib in recurrent ovarian cancer and primary peritoneal carcinomatosis: A gynecologic oncology group trial. J. Clin. Oncol. 2011, 29, 69-75. [CrossRef] [PubMed]
80. Heerboth, S.; Lapinska, K.; Snyder, N.; Leary, M.; Rollinson, S.; Sarkar, S. Use of epigenetic drugs in disease: An overview. Genet. Epigenet. 2014, 6, 9-19. [PubMed]
81. Housman, G.; Byler, S.; Heerboth, S.; Lapinska, K.; Longacre, M.; Snyder, N.; Sarkar, S. Drug Resistance in Cancer: An Overview. Cancers 2014, 6, 1769-1792. [CrossRef] [PubMed]
82. Sarkar, S.; Longacre, M.; Tatur, N.; Heerboth, S.; Lapinska, K. Encyclopedia of Analytical Chemistry; Histone Decatylases (HDACs): Function, Mechanism & Inhibition; Wiley Online Library: London, UK, 2014; pp. 1-9.
83. Chang, H.G.; Kim, S.J.; Chung, K.-W.; Noh, D.-Y.; Kwon, Y.; Lee, E.S.; Kang, H.-S. Tamoxifen-resistant breast cancers show less frequent methylation of the estrogen receptor beta but not the estrogen receptor alpha gene. J. Mol. Med. 2005, 83, 132-139. [CrossRef] [PubMed]
84. Glasspool, R.M.; Teodoridis, J.M.; Brown, R. Epigenetics as a mechanism driving polygenic clinical drug resistance. Br. J. Cancer 2006, 94, 1087-1092. [CrossRef] [PubMed]
85. Strathdee, G.; Vass, J.K.; Oien, K.A.; Siddiqui, N.; Curto-Garcia, J.; Brown, R. Demethylation of the MCJ gene in stage III/IV epithelial ovarian cancer and response to chemotherapy. Gynecol. Oncol. 2005, 97, 898-903. [CrossRef] [PubMed]
86. Gifford, G.; Paul, J.; Vasey, P.A.; Kaye, S.B.; Brown, R. The acquisition of hMLH1 methylation in plasma DNA after chemotherapy predicts poor survival for ovarian cancer patients. Clin. Cancer Res. 2004, 10, 4420-4426. [CrossRef] [PubMed]
87. Matei, D.E.; Nephew, K.P. Epigenetic therapies for chemoresensitization of epithelial ovarian cancer. Gynecol. Oncol. 2010, 116, 195-201. [CrossRef] [PubMed]
88. Cacan, E.; Ali, M.W.; Boyd, N.H.; Hooks, S.B.; Greer, S.F. Inhibition of HDAC1 and DNMT1 modulate RGS10 expression and decrease ovarian cancer chemoresistance. PLoS ONE 2014, 9, e87455. [CrossRef] [PubMed]
89. Agrawal, S.; Unterberg, M.; Koschmieder, S.; zur Stadt, U.; Brunnberg, U.; Verbeek, W.; Büchner, T.; Berdel,W.E.; Serve, H.; Müller-Tidow, C. DNA methylation of tumor suppressor genes in clinical remission predicts the relapse risk in acute myeloid leukemia. Cancer Res. 2007, 67, 1370-1377. [CrossRef] [PubMed]
90. Balch, C.; Huang, T.H.-M.; Brown, R.; Nephew, K.P. The epigenetics of ovarian cancer drug resistance and resensitization. Am. J. Obstet. Gynecol. 2004, 191, 1552-1572. [CrossRef] [PubMed]
91. Mataga, M.A.; Rosenthal, S.; Heerboth, S.; Devalapalli, A.; Kokolus, S.; Evans, L.R.; Longacre, M.; Housman, G.; Sarkar, S. Anti-breast cancer effects of histone deacetylase inhibitors and calpain inhibitor. Anticancer Res. 2012, 32, 2523-2529. [PubMed]
92. Lapinska, K.; Housman, G.; Heerboth, S.; Longacre, M.; Sarkar, S. Anticancer effects of histone deacetylase inhibitors and calpain inhibitor. Anticancer Res. 2012, 32, 2523-2529.
93. Fujji, S.; Luo, R.Z.; Yuan, J.; Kadota, M.; Oshimura, M.; Dent, S.R.; Kondo, Y.; Issa, J.J.; Bast, R.C.; Yu, Y. Reactivation of the silenced and imprinted alleles of ARHI is associated with increased histone H3 acetylation and decreased histone H3 lysine 9 methylation. Hum. Mol. Genet. 2003, 12, 1791-1800. [CrossRef]
94. Frew, A.J.; Lindemann, R.K.; Martin, B.P.; Clarke, C.J.P.; Sharkey, J.; Anthony, D.A.; Banks, K.-M.; Haynes, N.M.; Gangatirkar, P.; Stanley, K.; et al. Combination therapy of established cancer using a histone deacetylase inhibitor and a TRAIL receptor agonist. Proc. Natl. Acad. Sci. USA 2008, 105, 11317-11322. [CrossRef] [PubMed]
95. Juergens, R.A.; Wrangle, J.; Vendetti, F.P.; Murphy, S.C.; Zhao, M.; Coleman, B.; Sebree, R.; Rodgers, K.; Hooker, C.M.; Franco, N.; et al. Combination epigenetic therapy has efficacy in patients with refractory advanced non-small cell lung cancer. Cancer Discov. 2011. [CrossRef] [PubMed]
96. Sarkar, S.; Faller, D.T. T-oligos inhibit growth and induce apoptosis in human ovarian cancer cells. Oligonucleotides 2011, 21, 47-53. [CrossRef] [PubMed]
97. Pchejetski, D.; Alfraidi, A.; Sacco, K.; Alshaker, H.; Muhammad, A.; Monzon, L. Histone deacetylases as new therapy targets for platinum-resistant epithelial ovarian cancer. J. Cancer Res. Clin. Oncol. 2015, 1-13. [CrossRef] [PubMed]
98. Gyparaki, M.T.; Papavassiliou, A.G. Epigenetic pathways offer targets for ovarian cancer treatment. Clin. Ovarian Other Gynecol. Cancer 2014, 4, 71. [CrossRef]
99. Dong, Y.; Batra, J.; Anand, K.S.; Bapat, S.; Clements, A.J. Transforming the future of treatment for ovarian cancer. Clin. Exp. Pharmacol. 2014, 4, 3.
100. Curtis, C.; Shah, S.P.; Chin, S.-F.; Turashvili, G.; Rueda, O.M.; Dunning, M.J.; Speed, D.; Lynch, A.G.; Samarajiwa, S.; Yuan, Y.; et al. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature 2012, 486, 346-352. [CrossRef] [PubMed]
101. Byler, S.; Goldgar, S.; Heerboth, S.; Leary, M.; Housman, G.; Moulton, K.; Sarkar, S. Genetic and epigenetic aspects of breast cancer progression and therapy. Anticancer Res. 2014, 34, 1071-1077. [PubMed]